Cargando…

An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure

Amyloid beta (Aβ) oligomers are the most neurotoxic aggregates causing neuronal death and cognitive damage. A detailed elucidation of the aggregation pathways from oligomers to fibril formation is crucial to develop therapeutic strategies for Alzheimer’s disease (AD). Although experimental technique...

Descripción completa

Detalles Bibliográficos
Autores principales: Boopathi, Subramanian, Poma, Adolfo B., Garduño-Juárez, Ramón
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509255/
https://www.ncbi.nlm.nih.gov/pubmed/34639140
http://dx.doi.org/10.3390/ijms221910798
_version_ 1784582293820538880
author Boopathi, Subramanian
Poma, Adolfo B.
Garduño-Juárez, Ramón
author_facet Boopathi, Subramanian
Poma, Adolfo B.
Garduño-Juárez, Ramón
author_sort Boopathi, Subramanian
collection PubMed
description Amyloid beta (Aβ) oligomers are the most neurotoxic aggregates causing neuronal death and cognitive damage. A detailed elucidation of the aggregation pathways from oligomers to fibril formation is crucial to develop therapeutic strategies for Alzheimer’s disease (AD). Although experimental techniques rely on the measure of time- and space-average properties, they face severe difficulties in the investigation of Aβ peptide aggregation due to their intrinsically disorder character. Computer simulation is a tool that allows tracing the molecular motion of molecules; hence it complements Aβ experiments, as it allows to explore the binding mechanism between metal ions and Aβ oligomers close to the cellular membrane at the atomic resolution. In this context, integrated studies of experiments and computer simulations can assist in mapping the complete pathways of aggregation and toxicity of Aβ peptides. Aβ oligomers are disordered proteins, and due to a rapid exploration of their intrinsic conformational space in real-time, they are challenging therapeutic targets. Therefore, no good drug candidate could have been identified for clinical use. Our previous investigations identified two small molecules, M30 (2-Octahydroisoquinolin-2(1H)-ylethanamine) and Gabapentin, capable of Aβ binding and inhibiting molecular aggregation, synaptotoxicity, intracellular calcium signaling, cellular toxicity and memory losses induced by Aβ. Thus, we recommend these molecules as novel candidates to assist anti-AD drug discovery in the near future. This review discusses the most recent research investigations about the Aβ dynamics in water, close contact with cell membranes, and several therapeutic strategies to remove plaque formation.
format Online
Article
Text
id pubmed-8509255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85092552021-10-13 An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure Boopathi, Subramanian Poma, Adolfo B. Garduño-Juárez, Ramón Int J Mol Sci Review Amyloid beta (Aβ) oligomers are the most neurotoxic aggregates causing neuronal death and cognitive damage. A detailed elucidation of the aggregation pathways from oligomers to fibril formation is crucial to develop therapeutic strategies for Alzheimer’s disease (AD). Although experimental techniques rely on the measure of time- and space-average properties, they face severe difficulties in the investigation of Aβ peptide aggregation due to their intrinsically disorder character. Computer simulation is a tool that allows tracing the molecular motion of molecules; hence it complements Aβ experiments, as it allows to explore the binding mechanism between metal ions and Aβ oligomers close to the cellular membrane at the atomic resolution. In this context, integrated studies of experiments and computer simulations can assist in mapping the complete pathways of aggregation and toxicity of Aβ peptides. Aβ oligomers are disordered proteins, and due to a rapid exploration of their intrinsic conformational space in real-time, they are challenging therapeutic targets. Therefore, no good drug candidate could have been identified for clinical use. Our previous investigations identified two small molecules, M30 (2-Octahydroisoquinolin-2(1H)-ylethanamine) and Gabapentin, capable of Aβ binding and inhibiting molecular aggregation, synaptotoxicity, intracellular calcium signaling, cellular toxicity and memory losses induced by Aβ. Thus, we recommend these molecules as novel candidates to assist anti-AD drug discovery in the near future. This review discusses the most recent research investigations about the Aβ dynamics in water, close contact with cell membranes, and several therapeutic strategies to remove plaque formation. MDPI 2021-10-06 /pmc/articles/PMC8509255/ /pubmed/34639140 http://dx.doi.org/10.3390/ijms221910798 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Boopathi, Subramanian
Poma, Adolfo B.
Garduño-Juárez, Ramón
An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
title An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
title_full An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
title_fullStr An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
title_full_unstemmed An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
title_short An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
title_sort overview of several inhibitors for alzheimer’s disease: characterization and failure
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509255/
https://www.ncbi.nlm.nih.gov/pubmed/34639140
http://dx.doi.org/10.3390/ijms221910798
work_keys_str_mv AT boopathisubramanian anoverviewofseveralinhibitorsforalzheimersdiseasecharacterizationandfailure
AT pomaadolfob anoverviewofseveralinhibitorsforalzheimersdiseasecharacterizationandfailure
AT gardunojuarezramon anoverviewofseveralinhibitorsforalzheimersdiseasecharacterizationandfailure
AT boopathisubramanian overviewofseveralinhibitorsforalzheimersdiseasecharacterizationandfailure
AT pomaadolfob overviewofseveralinhibitorsforalzheimersdiseasecharacterizationandfailure
AT gardunojuarezramon overviewofseveralinhibitorsforalzheimersdiseasecharacterizationandfailure